Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Brazil / NCT06169241
Recruiting Phase EARLY_PHASE1

Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients

NCT06169241 · tracked via the Priya Life Science Brazil tracker
Sponsor
National Institute of Cardiology, Laranjeiras, Brazil
Phase
Phase EARLY_PHASE1
Started
2023-11-01
Last updated
2026-04-13

Condition(s) studied

Arterial HypertensionResistant HypertensionMicrovascular FunctionNitrate Supplementation

Investigational drug(s) / intervention(s)

Beetroot extractPlacebo

Beetroot extract: Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.

Placebo: The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.

Study summary

Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days. Exclusion Criteria: * neoplasms * heart failure * use of medications with nitrate in their formula * patients undergoing renal denervation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Institute of Cardiology Rio de Janeiro Brazil Recruiting

More National Institute of Cardiology, Laranjeiras, Brazil trials in Brazil

The Evolution of Systemic Microvascular Reactivity in Heart Transplant Patients Recruiting
Vascular Aging and Microcirculation: Physiological Aspects of Vascular Aging in the Elderly Population (VAMP-Aging) Starting soon
Acute Effects of Powdered Beetroot Extract Supplementation on the Microcirculation of Resistant Hypertensive Individuals Enrolling by invitation

Other trials for the same condition

Resistant Hypertension An Open, Complicated ("Cum Plicare") or Complex ("Cum Plexus") Syndrome? Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06169241 on ClinicalTrials.gov ↗ ← All trials in Brazil